BioXcel Therapeutics Inc. (BTAI) 正积极推进其药物Igalmi®的适用范围扩展。公司计划于本月内向美国食品药品监督管理局(FDA)提交补充新药申请(sNDA),核心目标是寻求批准该药物可用于居家环境。
此举若获成功,将标志着Igalmi®在应用场景上的重要突破,为患者提供更便捷的治疗选择。目前,该申请的具体细节和预期时间表备受市场关注。
BioXcel Therapeutics Inc. (BTAI) 正积极推进其药物Igalmi®的适用范围扩展。公司计划于本月内向美国食品药品监督管理局(FDA)提交补充新药申请(sNDA),核心目标是寻求批准该药物可用于居家环境。
此举若获成功,将标志着Igalmi®在应用场景上的重要突破,为患者提供更便捷的治疗选择。目前,该申请的具体细节和预期时间表备受市场关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.